Adrenal insufficiency is a condition in which the adrenal glands do not produce adequate steroid hormones, including cortisol and sometimes aldosterone. Deficiency can lead to fatigue, hypotension, gastrointestinal symptoms, and in severe stress states adrenal crisis.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
The FDA has approved Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer based on trial data showing improved survival. Separately, the agency granted Breakthrough Therapy designation to Lilly's sofetabart mipitecan for the same condition, expediting development of the antibody-drug conjugate.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07168122 |
Establishment and Clinical Application of Reference Intervals of Salivary Cortisol |
RECRUITING | |
| NCT06980753 |
Continuous Steroid Monitoring in Interstitial Fluid With Wearable and Nanoparticle-enhanced Biosensors for Improved Management of Adrenal Disorders |
NOT_YET_RECRUITING | NA |
| NCT06955286 |
Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion |
RECRUITING | |
| NCT06861530 |
A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children |
RECRUITING | |
| NCT06637722 |
Self-management in Patients With Adrenal Insufficiency. |
ACTIVE_NOT_RECRUITING | |
| NCT06608433 |
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function |
COMPLETED | NA |
| NCT06435481 |
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics |
NOT_YET_RECRUITING | PHASE4 |
| NCT06430528 |
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement |
RECRUITING | |
| NCT06309498 |
Residual Adrenal Function in Addison's Disease |
RECRUITING | |
| NCT06260462 |
Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency |
COMPLETED | PHASE3 |
